Printer Friendly

IDC'S VIROTECH UNIT TO COMMENCE ANIMAL STUDIES ON AIDS DRUGS

 MINNEAPOLIS, April 1 /PRNewswire/ -- Impression Delivery Corporation (IDC), through its Virotech subsidiary, announced today that it has contracted for animal studies in connection with its two AIDS drugs.
 The animal studies follow the successful results of drug synsethesis completed earlier this week, and will be conducted by the Southern Research Institute at Frederick Research Center, Frederick, Maryland. Under the provisions of the contract, the studies will commence on or about April 20, 1993. Under regulations of the US Food and Drug Administration (FDA), the Acute Oral Toxicity Studies are required to establish the safety of the drugs prior to the company's application for human clinical trials.
 Concurrently, Virotech has formed an alliance with SST Corporation of Clifton, N.J. whereby SST will provide technical support in the areas of synthetic organic chemistry and regulatory affairs. Additionally, SST will assist Virotech in identifying potential third party relationships with respect to future agreements for drug manufacturing, marketing, and licensing.
 Dr. John St. Cyr, M.D., Ph.D., Virotech's president, stated, "We are extremely pleased with our progress to date. Both the Southern Research Institute and SST Corporation are extremely well regarded in their respective fields."
 Impression Delivery Corporation is a Minneapolis-based holding company with operating subsidiaries engaged in the food industry, biotechnology, and merchandising.
 -0- 4/1/93
 /CONTACT: Tom de Petra of de Petra & Associates, 612-338-7630 or 800-969-7630, for Impression Delivery Corporation/


CO: Impression Delivery Corporation ST: Minnesota IN: SU:

KH -- MN008 -- 2160 04/01/93 15:27 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 1, 1993
Words:248
Previous Article:NORTHWEST TELEPRODUCTIONS ANNOUNCES AGREEMENT IN PRINCIPLE
Next Article:UNDERWRITERS LABORATORIES INC. OPENS SUBSIDIARY IN JAPAN
Topics:


Related Articles
BIOMUNE SYSTEMS, INC. ANNOUNCES PRECLINICAL DRUG FOR PREVENTING AND TREATING CRYPTOSPORIDIOSIS IN ANIMALS
VIROTECH, INC. NAMES MEDICAL ADVISORY BOARD
IMPRESSION DELIVERY CORPORATION RESPONDS TO STAR TRIBUNE ARTICLE
IDC'S VIROTECH UNIT EXECUTES LETTER OF INTENT WITH ORGANETICS, LTD.
IDC HOLDINGS, LTD. ESTABLISHES NEW MANAGEMENT TEAM
IDC'S VIROTECH UNIT SECURES FAVORABLE TEST RESULTS WITH ANTI-HIV DRUG
VIROTECH DRUG IS INCLUDED IN NCI PRE-CLINICAL ANTI-TUMOR DRUG DISCOVERY SCREENING PROGRAM
AGOURON BEGINS CLINICAL TESTING OF ANTI-HIV DRUG
FDA Clears Hybridon's IND For New Drug To Combat Systemic CMV In Immunocompromised Patients
LXR Biotechnology Inc. Announces Completion of Phase I Trials for Lexirin

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters